Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (ATNM)
NYSE MKT:ATNM
Actinium Pharmaceuticals (ATNM) Stock Price & Analysis
1,836 Followers
ATNM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.87 - $15.12
Previous Close$6.21
Volume140.60K
Average Volume (3M)163.49K
Market Cap
$170.08M
Enterprise ValueN/A
Total Cash (Recent Filing)$91.28M
Total Debt (Recent Filing)$9.15M
Price to Earnings (P/E)-3.5
Beta0.69
Next Earnings
Mar 15, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding26,997,587
10 Day Avg. Volume215,626
30 Day Avg. Volume163,487
Standard Deviation0.24
R-Squared0.00745
Alpha0.00238
Financial Highlights & Ratios
Price to Book (P/B)3.20
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$27.93Price Target Upside345.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Actinium Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $5.87 and its highest was $15.12 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Currently, no data Available
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Mar 15, 2024 which is in 171 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 26,997,587 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Royce & Associates LLC. It holds Actinium Pharmaceuticals’s shares valued at 371K.
---
Actinium Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.93 (345.45% Upside)
$27.93 (345.45% Upside)
Blogger Sentiment
Bullish
ATNM Sentiment 100%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.93%
12-Months-Change
Fundamentals
Return on Equity
-70.61%
Trailing 12-Months
Asset Growth
-18.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
Top 5 ETFs holding ATNM
Vanguard Total Stock Market ETF
$4.77M
Vanguard Russell 3000 ETF
$9.85K
Dimensional US Core Equity 1 ETF
$50.40
Up to five ETFs with an Outperform Smart Score that hold ATNM. The ETFs are listed according to market value of ATNM within the ETF
Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.
Atossa Therapeutics
―
Brainstorm Cell Therapeutics
―
Bio-Path Holdings
―
Cellectar Biosciences
―
---